What is Electra Therapeutics?
Electra Therapeutics operates as a specialized biotechnology firm dedicated to the development of first-in-class therapies that modulate immune cell activity. The company's core innovation, ELA026, represents a significant advancement in monoclonal antibody technology, designed to selectively deplete pathological myeloid cells and T lymphocytes. By focusing on novel targets within the immunology and oncology landscapes, Electra is building a robust portfolio that includes the ELA822 program, which aims to address activated T lymphocytes. This strategic focus on immune-mediated disease pathways allows the company to maintain a competitive edge in the rapidly evolving biopharmaceutical market, bridging the gap between fundamental scientific discovery and pivotal clinical development.
How much funding has Electra Therapeutics raised?
Electra Therapeutics has raised a total of $401.2M across 3 funding rounds:
Series B
$84M
Series C
$183M
Stock/Share Issuance
$134.2M
Series B (2022): $84M with participation from Cowen Healthcare Investments, Westlake Village BioPartners, New Leaf Venture Partners, Redmile Group, Cormorant Asset Management, RA Capital Management, and OrbiMed
Series C (2025): $183M led by Sanofi, EQT, OrbiMed, Mubadala, and Blue Owl
Stock/Share Issuance (2025): $134.2M, investors not publicly disclosed
Key Investors in Electra Therapeutics
OrbiMed
OrbiMed is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals and medical devices to support companies from early-stage ventures to established organizations.
Sanofi
Sanofi is a global biopharmaceutical leader dedicated to scientific innovation, focusing on the discovery and delivery of medicines across immunology, oncology, and rare diseases.
EQT
EQT is a thematic investment platform that partners with companies across their development stages, providing capital and expertise to drive growth in the healthcare and technology sectors.
What's next for Electra Therapeutics?
With the recent influx of capital, Electra Therapeutics is well-positioned to advance its lead candidate, ELA026, through pivotal clinical trials while simultaneously scaling its research and development infrastructure. The company's strategic roadmap emphasizes the expansion of its SIRP-targeted programs, which hold significant potential for addressing diverse indications in immunology and inflammation. As Electra transitions into more advanced stages of clinical validation, the focus will likely shift toward regulatory milestones and potential commercialization partnerships. The backing from a consortium of global life science investors provides the necessary financial runway to sustain long-term innovation cycles and solidify the company's footprint in the global therapeutic market.
See full Electra Therapeutics company page
